von Rotz R

Reconnect Labs AG, Winterthur, Switzerland.

7 papers · ORCID

ArticleAyahuasca

Population pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjects.

Äbelö A, Smallridge JW, von Rotz R +4

ArticlePsilocybin

Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial.

Rieser NM, Bitar R, Halm S +14

ArticleAyahuasca

Examining the pharmacokinetic and pharmacodynamic interaction of N,N-dimethyltryptamine and harmine in healthy volunteers: Α factorial dose-escalation study.

Egger K, Jareño Redondo J, Müller J +13

ArticlePsilocybin

Psilocybin increases emotional empathy in patients with major depression.

Jungwirth J, von Rotz R, Dziobek I +2

ArticleAyahuasca

Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine.

Dornbierer DA, Marten L, Mueller J +11

ArticlePsilocybin

TMS-EEG and resting-state EEG applied to altered states of consciousness: oscillations, complexity, and phenomenology.

Ort A, Smallridge JW, Sarasso S +7

ArticlePsilocybin

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.

von Rotz R, Schindowski EM, Jungwirth J +9